Both the triplet and doublet were generally well-tolerated with no unexpected toxicities. Grade 3 or higher adverse events (AEs) were seen in 58%, 50% and 61% of patients in the triplet, doublet, and control arms, respectively. The most common grade 3 or higher AEs reported in patients treated with the triplet were diarrhea (10% vs 2% in the doublet arm and 10% in the control arm), abdominal pain (6% vs 2% in the doublet arm and 5% in the control arm) and nausea (5% vs &LT1% in the double arm and 1% in the control arm). The trial is being conducted at over 200 investigational sites in North America, South America, Europe, and the Asia Pacific region. References: 1. U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW TO SNDA FOR BRAFTOVI® (ENCORAFENIB) IN COMBINATION WITH ERBITUX® (CETUXIMAB) (BRAFTOVI DOUBLET) FOR THE TREATMENT OF BRAFV600E-MUTANT METASTATIC COLORECTAL CANCER AFTER PRIOR THERAPY [news release].